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Prostate cancer (PCa) is the most commonly diagnosed male malignancy and the second 
leading cause of male cancer death in the Western world. In the United States of America 
(USA), African American men (AAM) have among the highest rates of PCa in the world. 
They develop the disease 1.5 times more frequently than European American men (EAM) of 
the same age .The mortality rate is approximately two to three times higher for AAM 
compared to EAM.
There is a dearth of literature exploring the incidence and treatment outcomes of this disease 
based on racial profiling in a South African population. This study aims to evaluate racial 
disparities with a focus on patients with PCa managed in the public health care sector in the 
province of Kwazulu Natal (KZN).
Patients and methods
The study was a retrospective analysis of patients with PCa treated at Inkosi Albert Luthuli 
Central Hospital and Addington Hospital, which are both based in the Durban Metropolitan 
area in the province of KZN. Data extracted from the folders of patients with PCa who 
presented between March 2003 and December 2007 were collated onto a data capture form 
and analysed. Patient data were analysed according to the following categories:
 Patient demographics; 
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 Patient follow-up period;
 Disease risk profile;
 Response to treatment;
 Compliance on treatment. 
SPSS version 15.0 was used to analyse the data. Within each disease category, the response 
variables were analysed by race group using non-parametric Kruskal-Wallis tests. Multiple 
comparisons were made using pairwise Mann-Whitney tests and Bonferroni adjusted 
significance levels according to the number of multiple comparisons made. In order to control 
for other confounding factors such as age, serum PSA levels and compliance, Cox 
proportional hazards models were used. Hazard ratios and 95% confidence intervals were also 
reported.   
Results
In KZN, the majority of the population is classified as blacks (82.9%). The Indian population 
group makes up 9.0% of the provincial population while white and coloured people make up 
6.1% and 2.0% of the provincial population respectively. In this study population, Blacks 
made up 57.7% and whites made up 27.5%, followed by 11.4% of Indians and 3.4% of 
coloureds. The racial frequency distribution of the study population demonstrated that whites 
had a higher incidence of PCa when analysing their demographic profile in the province. 
Blacks had the highest median total serum prostate specific antigen (PSA) levels on 
presentation. When compared to that of the white study population, this was found to be 
statistically significant (p < 0.001). There was a significant association between stage of
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disease and race (p = 0.001). In the black group, a greater proportion had metastatic rather 
than localised or locally advanced disease, and in the white group the converse was seen, 
whereas in the Indian and coloured groups an almost equal proportion had localised or locally 
advanced disease versus metastatic disease. A crude analysis of progression free survival 
(PFS) data in patients with metastatic disease demonstrated that PFS was significantly (p = 
0.003) longer for whites compared to blacks. Cox regression analysis did not confirm the 
influence of race on disease progression but this was confounded by incomplete data. 
Discussion
The high incidence of whites in our study population relative to their racial distribution in the 
province may be explained by better educational and awareness levels of PCa and better 
access to healthcare facilities in this race group as compared to blacks. The data demonstrating 
a more advanced stage of disease presentation and higher median PSA levels in the black 
population may be reflective of an informational void on screening and awareness of PCa 
and/or a more aggressive disease course in this population group. The hypothesis that the 
black population may have a more aggressive disease course is given further credence by the 
crude analysis data suggesting a longer PFS for whites when compared to blacks. 
Conclusions
This study invites further exploration of racial trends in PCa incidence, risk profile and 
outcomes amongst the diverse population groups of SA. 
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Based on the results of this study, the implementation of targeted study initiatives with end 
points designed to detect the disease earlier in the black population and begin appropriate 
management is justified. A commitment to address gross disparities in socio-economic status 
between the race groups is paramount to eradicate the racial bias that exists in terms of 




PCa is the most commonly diagnosed male malignancy and the second leading cause of male 
cancer death in the Western world [1].
PCa incidence increased in Western countries during the late 1980s and 1990s largely owing
to serum PSA testing [2]. The highest rates of PCa are in Scandinavia, where it is the leading 
cause of male cancer death. The lowest recorded rates are in Asia. In the United Stated of 
America (USA), incidence and mortality are higher among AAM. A 30- to 50-fold difference 
in risk between AAM at the highest end of the spectrum and native Japanese at its lowest end 
has been reported [1].
Although PCa is a major cause of cancer-related death, mortality rates have increased less 
than the incidence rates in many countries. Indeed, in the USA, Canada, and several 
European countries, recent declines in PCa mortality and metastatic disease have been 
reported. The decline in mortality may be partly due to PSA screening [2].
1.1 Prostate cancer screening initiatives
Screening for PCa is a controversial issue in health care in general and urological practice in 
particular. The merits of introducing national PCa screening programmes in Europe are 
currently being debated. At present, the evidence to support the implementation of national
PCa screening programmes is inadequate. These programmes have therefore not been 
introduced in a systematic fashion outside randomised clinical trial settings [2]. Clinical 
practice patterns as well as proposed guidelines with regard to PSA screening or testing 
remains controversial and differs among countries. 
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In the USA, guidelines currently favour the principle of screening for PCa. The American 
Cancer Society recommends screening for all men aged at least 50 years, although it 
acknowledges that men should be educated about issues regarding early detection and PCa
treatment, thereby aiding full participation in decision making. The American Urological 
Association recommends that healthy men over the age of 50 should consider PCa screening 
with a digital rectal examination (DRE) and a PSA test [2].
1.2 Prostate cancer screening in South Africa (SA): The pitfalls of a disjointed 
healthcare system
In SA, there is no national PCa screening program in existence. PCa screening is poorly co-
ordinated and is often based on socio-economic factors, educational levels and health care 
access.
The healthcare system reflects and represents the broader fragmentation of society within SA. 
The health system is primarily split on racial grounds: the African population, and to a lesser 
extent the coloured population, use the public sector and the white population, and to a 
slightly lesser extent the Indian population, use the private sector. This racial fragmentation
is, however, combined both with insurance status and income level (the uninsured poor use 
the public sector and the insured rich use the private sector), and with geography (the rural 
population uses the public sector and the (formal) urban population, the private sector) [3].
As a consequence, it is largely the insured rich, urban population groups with access to 
private healthcare that are better able to utilise PCa screening tools. 
In a clinical study assessing the feasibility of detecting early-stage PCa in the primary 
healthcare setting in SA, it is of some concern that prostate biopsies were only obtained in 
19% of black and 47% of coloured men with a serum PSA of > or = 4.0 ng/ml [4]. Further 
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research is required to ascertain the factors associated with patient reluctance to undergo 
prostate biopsies.
There is a dearth of literature exploring the incidence and treatment outcomes of this disease 
based on racial profiling in a South African population. This study was designed to provide 
some insight into this topic focusing on patients with PCa managed in the public health care 
sector in the province of KZN. 
1.3 Kwazulu Natal: A melting pot of racial and socio-economic diversity
According to the National Census of 2001, KZN is home to about 21.0% of SA’s population, 
making it SA’s largest province. 
Various absolute and relative poverty lines are used in SA. In recent years, the
40th percentile cut-off point of adult equivalent per capita income has become quite a popular
poverty line. This was equal to R 5 057 per annum in 2000. These same national poverty 
lines are used for the provincial analysis as this allows for comparisons of poverty across 
provinces [5].
Measured by its total current income, KZN is the third richest province in SA. Although the 
people of KZN are in a relatively more secure financial standing, the province still 
experiences high poverty rates, inequalities in the distribution of income between various 
population subgroups, and unemployment [5].
Poverty rates vary significantly between racial groups. There is virtually no poverty among 
whites, and only 6.0% of the Asian population is poor. In sharp contrast, the poverty rates for 
coloured and black people are 17.2% and 64.4% respectively. Poverty is also clearly a rural 
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phenomenon, with the rural poverty rate estimated at 78.2% compared to 28.9% in urban 
areas. The poverty rate is also much higher among agricultural households (81.2%) than non-
agricultural households (49.5%) [5].
The socio-economic disparities highlighted between the different racial groups should 
hypothetically impact on incidence and treatment outcomes in patients with PCa. 
Disadvantaged socio-economic groups are hampered by poor accessibility and affordability 
of specialised healthcare services. 
Public healthcare oncology services are rendered exclusively in the Durban-Pietermaritzburg 
metropolitan areas. This may possibly impact on stage of disease at clinical presentation and 
compliance to treatment in patients with PCa that reside in outlying areas. 
1.4 . Incidence of prostate cancer in SA
In Africa, the reported incidence of PCa in different countries correlates directly with the per 
capita gross national product (GNP) i.e. countries with the highest incidence rates have the 
highest per capita GNP. One explanation may be that the risk of PCa is related to 
industrialisation, environmental pollution or dietary factors in more affluent populations. 
However, a more likely explanation is that improved access to medical facilities, with 
increased diagnosis and reporting of PCa, is responsible for the higher incidence rates in 
more affluent countries [6].
The South African National Cancer Registry was a pathology-based registry that published its 
last report of cancer statistics in SA in 2001 [7].
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Based on the South African National Cancer Registry figures from 1998 and 1999, PCa was 
the leading cancer reported in males, comprising 14% and 13% of all cancers reported in 
males in the respective years. The lifetime risk of developing PCa was 1 in 22 men in 1998 
and 1 in 24 in 1999 [7].
Being a pathology-based registry, it has the limitation of possible under-reporting of cases 
which may confound the true incidence of malignancies in SA. The discontinuation of the 
National Cancer Registry has also created a void in terms of analysing more recent patterns 
of incidence of the various malignancies, including PCa. 
1.5. Race based disparities in the incidence of prostate cancer in SA
Based on National Cancer Registry data, PCa was the leading cancer in all population groups 
over the two years, 1998 – 1999 (Table 1). White men comprised more than half of all PCa
cases reported during this period and had the highest incidence rate. PCa comprised on 
average 14% of all cancers reported in white males. The second highest incidence rates were 
observed in coloured men. These comprised on average 10% of all PCa cases. PCa comprised 
on average 15% of all coloured male cancers. Black men constituted about one third of all 
prostate cancers in this period. Asian and black men had the lowest rates, and the risk of 




N (Obs) Number of cases observed
N (Adj) Observed cases adjusted for unknown population group
Percent Percentage of all site cancers
Crude Number of cases per 100 000 of population
ASR Age standardised incidence rate per 100 000 (World standard 
population)
95% LCL 95% Lower confidence limit for ASR
95% UCL 95% Upper confidence limit for ASR
Cumrisk Cumulative lifetime incidence risk (0-74 years)
LR Lifetime risk (0-74 years) of developing a cancer expressed as 
1 in X number of people
Table 1: Summary statistics for prostate cancer in SA, 1998-1999 [7]
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The lifetime risk of PCa amongst the different race groups based on the South African 
National Cancer Registry data from 1999 is as follows: Asian 1:39, Black 1:50, Coloured 
1:19, White 1: 10, with a combined risk of 1:24 amongst all race groups [7].
The apparent lower incidence among black men in SA is most probably due to lower rates of 
diagnosis or reporting due to socio-economic reasons [6].
1.6. International race based comparisons of incidence
PCa rates for white South African men rank among the highest rates in the world (Table 2). 
South African incidence rates for PCa are higher than rates reported in many developing 
countries, particularly those in sub-Saharan Africa [7].
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Table 2: Prostate cancer age standardised rates (ASR) per 100 000 for selected 
populations [7]
In the USA, the converse holds true, with AAM having the highest rates of PCa in the world. 
They develop the disease 1.5 times more frequently than EAM of the same age. The reasons 
for the higher incidence rates in AAM remain unclear but are likely multifactorial, combining 
environmental and genetic factors [8].
Several studies have shown a higher average or mean total PSA and PSA density in AAM 
compared with EAM, even after controlling for tumour stage [6].
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The National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program 
currently collects and publishes cancer incidence and survival data from population-based 
cancer registries, covering approximately 26 percent of the USA population. Table 3
illustrates high incidence rates of PCa in blacks when compared to other race groups 
diagnosed in 2000-2004 in 17 SEER geographic areas [9].
Incidence Rates by Race
Race/Ethnicity Male
All Races 168.0 per 100,000 men
White 161.4 per 100,000 men
Black 255.5 per 100,000 men
Asian/Pacific Islander 96.5 per 100,000 men
American Indian/Alaska Native 68.2 per 100,000 men
Hispanic 140.8 per 100,000 men
Table 3: Incidence rates by race, SEER Cancer Statistics Review, 2000-2004 [9]
1.7. Race-based mortality rates
The mortality rate is approximately two to three times higher for AAM compared to EAM,
indicating that PCa is a major public health problem in this population [6].
There are no reliable age-adjusted PCa mortality rates available for African countries [6] and 




Table 4 illustrates mortality rates for men with PCa during the period 2000-2004 in the USA.
Death Rates by Race
Race/Ethnicity Male
All Races 27.9 per 100,000 men
White                                           25.6 per 100,000 men
Black 62.3 per 100,000 men
Asian/Pacific Islander 11.3 per 100,000 men
American Indian/Alaska Native 21.5 per 100,000 men
Hispanic 21.2 per 100,000 men
Table 4: Death rates by race, SEER Cancer Statistics Review, 2000-2004 [9]
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1.8. Exploring possible aetiological factors to account for racial differences in incidence 
and mortality
Table 5: USA Prostate cancer incidence and mortality, SEER Cancer Statistics Review, 
1975 to 2002 [9]
There are many postulated factors to account for the racial differences in the clinical profile 
of patients with PCa. Some of the implicated factors include hormonal, nutritional, genetic, 
behavioural, and environmental influences [6].
1.8.1 Possible factors accounting for racial differences in prostate cancer incidence
Genetic factors
The higher incidence of PCa among AAM may be explained by alterations in genes that 
control the androgen receptor, the 5-alphareductase (SRD5A2) or poly ADP-ribose 
polymerase (PADPRP) enzymes [6].
Dietary factors may also account for the higher PCa incidence in AAM. Diets containing a 
high fat content and large consumption of red meat may increase the risk, while a high intake 
of dietary phyto-oestrogens, tomato based products containing lycopene, selenium, vitamins 
E and D are thought to decrease the risk of developing PCa [6]. 
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Raised serum testosterone and dihydrotestosterone levels have not been convincingly 
associated with an increased risk of PCa. While some groups have reported that serum levels 
of these androgens are higher in patients with PCa than in age matched controls, others were 
not able to detect any differences. There are, however, reports documenting that mean serum 
testosterone levels are about 15% higher in young AAM compared with EAM, a difference 
that may be relevant to the increased PCa risk in AAM in later years [10].
1.8.2 Possible factors accounting for racial differences in prostate cancer mortality
The greater PCa mortality in AAM may be attributable to the higher incidence, as well as 
higher tumour stage and grade at presentation in this demographic group [6]. 
Differences in treatment may also account for the disparity in mortality rates between the 
racial groups. Several studies show that AAM tend to receive aggressive therapy more 
infrequently than EAM or they go untreated more often [10].
There have been reports that the tumour stage at diagnosis was inversely correlated with 
health insurance, income status, PCa awareness and previous participation in PSA screening
among AAM but not EAM. Studies have also demonstrated that socio-economic factors and 
limited access to healthcare contribute to the poorer outcomes in AAM even after adjusting 
for differences in pre-treatment disease characteristics [6].
The role of socio-economic factors was evaluated in a retrospective cohort study which 
compared the survival rates of black and white American men with PCa using a multivariate 
model including socio-economic status and treatment method. This study reported that 
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household income explained half of the difference in survival rates between the two groups, 
while lower surgical treatment rate in AAM accounted for 34% of the difference in survival 
[11]. 
Delayed diagnosis resulting from cultural differences, such as the fear of PCa diagnosis and 
rectal examination has also been hypothesised as a factor accounting for racial disparities in 
mortality rates [8].
However, the question of biologic differences remains, as stratification for socio-economic 
and educational level does not negate disparities in incidence and mortality. There is a 
suggestion that PCa among AAM is biologically more aggressive than among EAM based on 
data showing a younger age at presentation and greater risk of mortality in the former group. 
However, the majority of reports indicate that, when controlled for major prognostic factors, 
the outcome for clinically localised as well as advanced PCa is independent of race [6].
One of the few studies that explored the disease from a South African context analysed the
incidence and stage at presentation of PCa in black patients from Soweto, Johannesburg, and 
compared mortality to that of white patients [12]. Of the 101 black men recruited 
between1982-1984, 90 patients had stage D (metastatic) disease. An indirect analysis of 
mortality rates in comparison with studies done on white patients was inconclusive.
Chapter 2: Patients and methods
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Chapter 2: Patients and methods
2.1 Aim
The aim of this study was to examine racial differences in disease stage and risk profile at 
presentation in patients with PCa and to correlate this with treatment outcome.
Compliance was also assessed as a secondary endpoint to ascertain whether this may also 
contribute to outcome in different race groups.
2.2 Specific objectives
This study was designed to analyse whether patients with PCa in KZN, SA would 
demonstrate racial differences in incidence and mortality similar to that demonstrated 
between AAM and EAM with PCa in the USA. This would enable to us implement greater 
awareness campaigns and screening programmes in racial groups demonstrating higher 
incidence, more aggressive risk profile, higher disease stage at presentation and poorer 
treatment outcomes.
2.3 Method
The study design was in the form of a retrospective analysis of patients with PCa treated at 
Inkosi Albert Luthuli Central Hospital and Addington Hospital which are both based in the 
Durban Metropolitan area in the province of KZN. Data extracted from the folders of patients 
with PCa who presented between March 2003 and December 2007 were collated onto a data 
capture form (Appendix) and analysed.
This study was granted approval by the Faculty of Medical Ethics Committee and the 
postgraduate education committee of the University of KwaZulu-Natal.
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Patient data were analysed in the following categories:
 Patient demographics;
 Patient follow-up period; 
 Disease risk profile;
 Response to treatment;
 Compliance on treatment.
2.4 Analysis of patient demography
Patient demography was analysed in terms of:
 Age and 
 Race (race was assigned based on documentation from administrative staff). 
2.5 Analysis of follow-up period
The follow-up period in the different racial groups was defined as the time from first 
consultation to the date of data analysis. Follow-up period is highly skewed, with the median 
therefore representing the most appropriate measure of central tendency. 
2.6 Analysis of disease risk profile
Disease profile was based on the following parameters:
 Total Serum Prostatic Specific Antigen (PSA)
 Bone scan
 Pathological findings (Gleason score, Perineural invasion, High-grade prostatic 
intraepithelial neoplasia)
 Clinical stage/Pathological stage
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2.7 Analysis of treatment response 
The assessment of treatment response was first based on establishing defined disease 
categories and then using the varying study endpoints within each disease category to assess 
treatment response in the different race groups.
Definition of disease categories
Disease Categories were defined as follows:
 Localised Disease  
- Clinical Stage T1/T2
 Locally Advanced Disease 
- Clinical Stage T3/T4
 Biochemical Failure 
- Based on the American Society for Therapeutic Radiology and Oncology (ASTRO)
definition of 3 consecutive rises in serum PSA levels
 Metastatic Disease
- Presence of bone metastases as confirmed on radiographic evaluation
 Hormone Refractory Disease
- Progression of metastatic disease based on radiographic, clinical and/or biochemical 
parameters along with a serum testosterone < 50ng/ml
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Response to treatment was analysed using the following endpoints in the respective disease 
categories:
 Localised Disease – Clinical Stage T1/T2
i. Progression Free Survival (PFS)
 Locally Advanced Disease – Clinical Stage T3/T4
i. Progression Free Survival (PFS)
 Biochemical Failure
i. Progression Free Survival (PFS)
 Metastatic Disease – M1
i. Progression Free Survival (PFS)
 Hormone Refractory Disease
i. Time to Hormone Refractory disease (TTHRD)
ii. Progression Free Survival (PFS)
iii. Time to Biochemical Response on chemotherapy (TTBR) 
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Definitions of endpoints used:
The above-mentioned endpoints used for the disease categories to evaluate treatment 
response were defined as follows:
Progression free survival (PFS) in months
Progression is defined in terms of biochemical and/or radiographic and/or clinical 
parameters:
1. Biochemical: 
Biochemical progression differs for different disease categories:
 Localised/Locally Advanced Disease : 
Any rise in PSA after achieving PSA values <0.1 ng/ml post curative 
surgery or PSA <0.1 ng/ml post radical radiotherapy
 Biochemical Failure : 
Any subsequent rise in PSA after diagnosis of biochemical failure
 Metastatic Disease : 
Any further rise in PSA after diagnosis of metastatic disease
 Hormone Refractory Disease : 
Any further rise in PSA after diagnosis of hormone refractory disease




 Any new focus of skeletal or other metastases or 
 Progression of previously documented metastases based on RECIST 
Criteria: PD (progressive disease) = 20% increase in the sum of the 
longest diameter of target lesions.
3. Clinical: 
Defined as:
 Progression of clinical stage noted on digital rectal examination (DRE) or 
 Worsening of European Cooperative Oncology Group (ECOG)
performance status or 
 Progression of pain.
Time to hormone refractory disease (TTHRD)
Defined as the time from diagnosis of PCa to the development of hormone refractory disease.
Time to biochemical response on chemotherapy (TTBR)
Defined as time from initiation of chemotherapy to any subsequent decrease in PSA levels.
2.8 Analysis of compliance to treatment and follow-up
Assessment of compliance was based on the following factors: 
 History of missed appointments and
 Documented non-compliance on treatment.
Each of the above factors scored a solitary point for a tally of 2. Scores were tabulated and 
assessed to derive a scoring system reflecting patient compliance. 






Table 6: Compliance index
Statistical Analysis
SPSS version 15.0 was used to analyse the data. Within each disease category, the response 
variables defined previously were analysed by race group using non-parametric Kruskal-
Wallis tests. Multiple comparisons were made using pairwise Mann-Whitney tests and 
Bonferroni adjusted significance levels according to the number of multiple comparisons 
made. In order to control for other confounding factors such as age, serum PSA levels and 
compliance, Cox proportional hazards models were used. Hazard ratios and 95% confidence 




3.1Demographic profile of target population
Table 7: Age and racial composition of study population
3.1.1 Racial composition
The mean age, age range and racial composition of the study groups are shown in Table 7. 
3.1.2 Age at presentation in the different racial groups
The mean age at presentation was not significantly different among the different race groups
(Table 7).
Demographic Profile of 
Target Population
Blacks Whites Indians Coloureds Total





















Age range 51-88 53-79 51-86 57-76
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3.2 Analysis of follow-up period in the different racial groups






























































Table 8: Descriptives of mean, median, interquartile range and range for each race 
group
Race
















Table 9: Median follow-up duration in the racial groups
There was a statistically significant difference in median follow-up in the various racial
groups (p=0.023). Mann-Whitney tests were performed to analyse if the difference noted
among all race groups translated into differences between individual race groups. This did not 
reveal any statistically significant findings. 
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3.3 Evaluation of race and disease risk profile (Gleason score, PNI, PSA)
Table 10: Evaluation of race and risk profile (PSA, Gleason score, PNI)
Evaluation of race and 
disease risk profile
Blacks Whites Indians Coloureds p value
Median (inter-quartile 
range) total PSA (ng/ml)














Median (IQR) total PSA
(ng/ml) level for patients 















Median (IQR) total PSA

















Incidence of perineural 
invasion (%)
16.3 14.6 17.6 0 0.791











Incidence of evaluable GS 
score readings in each 
racial group (%)
73.3 70.7 88.2 60 0.468
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3.3.1 Race and total serum PSA level on presentation
Median total serum PSA at presentation in the whole study cohort (p<0.001) and in the group 
with localised or locally advanced PCa (p=0.008) displayed significant differences among the 
four race groups (Table 10). Bonferroni adjusted multiple comparison tests showed that there 
were only significant differences in the serum PSA levels when comparing the black and
white groups in the overall population (p<0.001) and in the non-metastatic disease group
(p=0.003). No statistically significant disparities were noted in the group of men with 
metastatic disease (Table 10). 
3.3.2 Race and incidence of perineural invasion
The incidence of perineural invasion was not found to be statistically significant between the 
different racial groups.
3.3.3 Race and Gleason score
As demonstrated in Table 10, the mean Gleason score did not differ significantly among the 
race groups (p=0.775), and there were also no significant differences noted in the incidence 
of evaluable GS readings in each racial group (p=0.468).
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3.4 Evaluation of race and clinical stage of disease
Evaluation of race and 
stage of disease 
Blacks Whites Indians Coloureds p value
No (%). of patients with 
localised and locally 
advanced disease
24 (27.9%) 27 (65.8%) 9 (52.9%) 2 (40%) 0.001
No (%). of patients with 
metastatic Disease 
62 (72.1%) 14 (34.2%) 8 (47.1%) 3 (60%)
No. of patients with 
biochemical failure 5 4 2 0
No. of patients with 
hormone refractory 
disease
13 4 1 1
Table 11: Evaluation of race and clinical stage of disease
Looking specifically at comparisons between the black and white populations of patients, it is 
demonstrated that in the black group, 27.9% had localised or locally advanced disease and 
72.1% had metastatic disease, whereas in the white group 65.8% had localised or locally 
advanced disease and 34.2% had metastatic disease.
There was a significant association between stage of disease and race (Pearson’s chi-square
test = 17.47, p = 0.001). In the black group, a greater proportion had metastatic rather than 
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localised or locally advanced disease, and in the white group the converse was seen, whereas 
in the Indian and coloured groups an almost equal proportion had localised or locally 
advanced disease versus metastatic disease. 
3.5. Comparison of race and treatment outcomes
3.5.1. Crude analysis of the impact of race on treatment outcomes
Crude analysis entailed non-parametric Kruskal-Wallis tests to compare study endpoints for 
treatment outcomes (PFS) between the races in different groups of cases.   
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Table 12: Crude analysis of race and treatment outcome endpoints
Localised and locally advanced disease:
The lack of statistically significant data when comparing PFS across racial groups is probably 
due to low patient numbers and large variation (Table 12). 
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PFS for hormone 
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When evaluating PFS data in patients with metastatic disease, an important distinction was 
that PFS was significantly (p = 0.003) longer for whites when compared to blacks (Table 12).
Hormone refractory disease:
Whites demonstrated the longest time to development of hormone refractory disease
(TTHRD) when compared to the other race groups (p= 0.025). Due to the small number of 
patients (n=19) with hormone refractory disease, these results must be treated with reserve. 
The small number of patients in this disease category also negatively impacted on analysis of 
PFS and TTBR. Longer follow-up is necessary to better evaluate treatment outcomes in 
patients with hormone refractory disease. 
3.5.2 Cox regression analysis of the impact of race on PFS
Adjusted analysis involved Cox regression analysis to evaluate the role of race while 
adjusting for confounders such as age, PSA and PNI. Gleason score could not be added to the 
models as there were too many missing values. 
3.5.2.1 Race as a risk factor for disease progression in patients with localised and locally 
advanced disease: 
N Percent






Cases dropped Cases with missing 
values
3 4.8%
Cases with negative 
time
0 .0%
Censored cases before 





a Dependent variable: Total PFS
Table 13: Case processing summary for Cox regression in localised and locally 
advanced disease
The number of cases evaluated using Cox regression statistical tests was 45 of the total 
presenting number of 62 patients with localised and locally advanced disease. 27.4% of 
patients presenting in these stage groupings were excluded for reasons including missing 
values and censored cases. 
Variables in the equation
B SE Wald df Sig. HR 95.0% CI for HR
Lower Upper
Race .351 3 .950





-11.365 1087.367 .000 1 .992 .000 .000 .
Indian vs. White -.366 .983 .138 1 .710 .694 .101 4.767
PSA .003 .002 2.769 1 .096 1.003 .999 1.007
Age -.063 .048 1.747 1 .186 .939 .854 1.031
PNI (yes vs. no) .273 .819 .111 1 .739 1.314 .264 6.540
B: Beta (coefficient)
SE: standard error 
Wald: Wald’s test statistic 
df: degrees of freedom 
Sig: p value 
HR: Hazard ratio
95% CI for HR: 95% confidence intervals for the hazard ratio
Table 14: Cox regression with all covariates in the model for disease progression in 
localised and locally advanced disease
Overall, race was not a significant predictor of PFS in those with localised or locally 
advanced disease (p = 0.950). Blacks were slightly more at risk than whites (HR = 1.266) but 
this was not statistically significant, and Indians were slightly less at risk than whites (HR = 
0.694, p = 0.710). PSA and the presence of PNI were not significant risk factors with p-
values of 0.096 and 0.739 respectively. An increase in age did not confer a significant 
protective effect (p = 0.186). 
Therefore none of the co-variates explored to ascertain their impact on the risk of progression 




3.5.2.2 Race as a risk factor for disease progression in patients with metastatic disease
a Dependent variable: Total PFS
Table 15: Case processing summary for Cox regression in metastatic disease
Only 48 of 87 patients presenting with metastatic disease were evaluated. 44.8% of cases 
were dropped with the predominant reason being censored data or missing data values. 
N Percent
Cases available in analysis Event (a) 20 23.0%
Censored 28 32.2%
Total 48 55.2%
Cases dropped Cases with missing 
values
11 12.6%




before the earliest 






Variables in the equation
B SE Wald df Sig. HR 95.0% CI for HR
Lower Upper
Race .279 3 .964
Black vs. White .277 .697 .158 1 .691 1.319 .337 5.169
Coloured vs. 
White
.650 1.368 .226 1 .635 1.916 .131 27.977
Indian vs. White .042 .966 .002 1 .965 1.043 .157 6.925
PSA .000 .000 7.133 1 .008 1.000 1.000 1.001
Age -.041 .030 1.935 1 .164 .959 .905 1.017
PNI -1.138 1.036 1.206 1 .272 .320 .042 2.444
B: Beta (coefficient)
SE: standard error 
Wald: Wald’s test statistic 
df: degrees of freedom 
Sig: p value
HR: Hazard ratio
95% CI for HR: 95% confidence intervals for the hazard ratio
Table 16: Cox regression with all covariates in the model for disease progression in 
metastatic disease
As seen in Table 16, race was not a significant predictor of disease progression in patients 
with metastatic disease (p = 0.964). The above data suggest that blacks and coloureds have a 
higher predisposition towards progression in metastatic disease than whites; however, these 
data must be treated with reserve due to large number of excluded cases and the non-
significant p values. A one year increase in age was non-significantly protective for 
progression (4.1% protective, p = 0.164). An increase in PSA significantly increased the risk 
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of progression (p = 0.008). A 10 ng/ml increase in PSA equated to a HR of 1.005 (95% CI 
1.001 – 1.008) while a 20 ng/ml increase in PSA increased the risk by 1.009 times (95 % CI 
1.002 -1.016). Presence of PNI was not significantly related to time to progression (p =
0.272).  
There were discordant racial differences in treatment outcomes noted when using crude 
analytic techniques and Cox regression techniques. While the crude analytic techniques 
reflected that PFS data for patients with metastatic disease were significantly superior for 
whites compared to blacks, this was not borne out with Cox regression techniques. This may 
be explained by the high proportion of cases dropped (44.8%) when using Cox regression and 
by the influence of confounding factors which were adjusted for in the Cox regression 
analysis. 
3.5.2.3 Race as a risk factor for disease progression in all stages (non-metastatic and 
metastatic) of prostate cancer
N Percent






Cases dropped Cases with missing 
values
14 9.4%




before the earliest 




a Dependent variable: Total PFS
Table 17: Case processing summary for Cox regression in all disease stages
The limitations posed by missing data are again in evidence with only 66.4% of the study 
population being evaluated. 
Variables in the equation
B SE Wald df Sig. HR 95.0% CI for Exp(B)
Lower Upper
Race .430 3 .934
Black vs. White .290 .493 .347 1 .556 1.337 .509 3.511
Coloured vs. 
White
.495 1.212 .167 1 .683 1.641 .153 17.650
Indian vs. White .084 .663 .016 1 .899 1.088 .297 3.988
PNI -.487 .619 .619 1 .431 .615 .183 2.066
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Age -.046 .022 4.516 1 .034 .955 .915 .996
PSA .000 .000 6.144 1 .013 1.000 1.000 1.001
B: Beta (coefficient)
SE: standard error 
Wald: Wald’s test statistic 
df: degrees of freedom 
Sig: p value 
HR: Hazard ratio
95% CI for HR: 95% confidence intervals for the hazard ratio
Table 18: Cox regression with all co-variates in the model for disease progression in all 
disease stages
Overall, race was not a significant risk factor for disease progression (p = 0.934). Blacks and 
coloureds showed a trend towards an increased risk for disease progression when compared 
to whites but this was not found to be statistically significant. Age was significantly 
protective (p = 0.034) by 4.5% with every one year increase in age. As PSA increased, so did 
the risk of disease progression (p = 0.013). A 10 ng/ml increase in PSA increased the risk by 
1.005 times (95% CI 1.002 – 1.008) and a 20 ng/ml increase in PSA increased the risk by 
1.010 times (95% CI 1.004 – 1.016). 
3.6 Exploring racial differences in compliance to follow-up and treatment 
Compliance score by race is shown in Table 19.  Compliance was used as an ordinal score 
ranging from 0 (good compliance) to 2 (poor compliance). The median score was compared 
between the race groups using the Kruskal-Wallis test.
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Kruskal-Wallis p = 0.027
Table 19: Evaluating race and compliance to treatment and follow-up
There was a significant association between race and compliance score (p = 0.027). The table 
shows that Indians were more inclined to have good compliance than the other race groups. 
The other race groups tended to have average compliance.  On account of the limited number 
of Indians included in the total study population, it is difficult to establish any definitive 
conclusions from the evaluation of compliance scores. 
These results do, however, underline the fact that despite the high poverty rates in black 
Africans (64.4%) compared to almost negligible poverty rates in whites [5], this did not 
translate into significant differences in compliance between these racial groups.
Compliance score Total
Good Average Poor
Race Black Count 30 52 4 86
% within Race 34.9% 60.5% 4.7% 100.0%
Coloured Count 1 4 0 5
% within Race 20.0% 80.0% .0% 100.0%
Indian Count 13 3 1 17
% within Race 76.5% 17.6% 5.9% 100.0%
White Count 17 23 1 41
% within Race 41.5% 56.1% 2.4% 100.0%
Total Count 61 82 6 149




The concepts of incidence and prevalence offer different information. Incidence shows the number of 
new cases diagnosed in a population during a specific period, while the study of prevalence will yield 
information about the number or proportion of people who have that disease in a specified period [8].
Unfortunately, the major differences in screening policies and health care systems between 
African countries, Europe, and the United States make the comparison in terms of PCa
incidence unreliable. Furthermore, the calculated incidence of diagnosed PCa cases does not 
reflect accurately the disease’s true prevalence. Denominators, which include population 
counts, are confounded by census difficulties in many African countries. PCa-specific 
mortality rates would probably lead to a better understanding of the natural history of the 
disease as it is less sensitive to screening practices. Unfortunately, these data are difficult to 
obtain [8].
AAM have been shown to have a higher susceptibility to the disease. While several factors 
have been hypothesised to account for this susceptibility, the reasons remain largely
unknown. As compared with African Americans, sub-Saharan populations previously showed
very low PCa rates, suggesting more the importance of environmental over genetic factors. 
However, PCa incidence trend in sub-Saharan African countries is now showing a marked 
increase, suggesting a changing disease pattern in PCa among these populations [8]. There 




This study, despite a relatively small study population and an evaluation of patients treated in 
the public health sector alone, does offer some insight into the incidence and course of PCa in 
the diverse population groups of KZN. 
4.1 Evaluation of racial incidence of prostate cancer in study population
AAM have some of the highest incidence and mortality rates of PCa in the world. Only 
multiple myeloma has greater black–white disparity than PCa [13].
In KZN, the majority of the population is classified as blacks (82.9%). The Indian population
group makes up 9.0% of the provincial population, white and coloured people make up 6.1%
and 2.0% of the provincial population, respectively [5].
In our study population, blacks formed the predominant race group in the study population, 
making up 57.7% of the total number of patients. Whites made up 27.5% of the study 
population, followed by 11.4% Indians and 3.4% coloureds. Based on these figures, there is a 
suggestion that whites have a relatively higher incidence of PCa when analysing their 
demographic profile in the province.
This may reflect socio-economic disparities between whites and blacks with the former 
having improved educational levels and better access to medical facilities, and consequently 
increased diagnosis of PCa. Black men are usually diagnosed because of long-standing 
symptoms or complications due to advanced disease e.g. paraparesis or paraplegia [6].
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4.2 Evaluation of age at presentation
Epidemiological data from the USA indicate that AAM present with PCa at a younger age 
than EAM (difference of about 3 years). 
The peak age for the occurrence of PCa is about a decade earlier in African countries than 
that reported in most developed countries. However, because the incidence of PCa increases 
with age, the peak age at presentation depends on the life expectancy of the population, 
which is substantially lower in African countries as compared to developed nations. [6]
The mean age in the different race groups in our study population ranged from 69.0 – 70.0 
with no statistically significant differences noted. 
4.3 Evaluation of race and risk profile
The most pertinent observation when exploring factors conferring a higher risk was the 
significantly higher median total PSA levels in blacks on presentation when compared to the 
other race groups, which is consistent with findings observed in AAM. 
4.4 Evaluation of race and clinical stage at presentation
An interesting observation was that white males tended to present more commonly with
localised or locally advanced (non-metastatic) PCa in this study population, while blacks 
tended to present more often with advanced disease. 
Extrapolating from studies performed in AAM, we may speculate whether this is a biological 
phenomenon reflecting a more aggressive disease course or whether it reflects differences in
socioeconomic factors, health seeking behaviour, literacy, cultural beliefs or 
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environmental/life-style factors. A body of evidence also indicates that PCa has a genetic
basis [10].
Evidence of an influence of socioeconomic status on stage at diagnosis and survival demonstrates that 
the cohort with advanced disease at initial diagnosis tends to be disproportionately poorer and less 
educated. The reasons why the poor present with more advanced stages are unclear. They may relate 
to diet and other environmental influences, or it may relate to less attention to health on the part of the 
poor. Lack of health insurance, a more specific factor than low socio-economic status, has been 
associated with an increased risk of a diagnosis of metastatic PCa [13].
These trends noted in the influence of socio-economic status on stage at diagnosis and survival 
may assume greater importance in SA on account of the significant racial disparities in socio-
economic status. The average household incomes of white, and to lesser extent Asian households, 
are much higher than those of black and coloured households [5] and this may impact on the 
greater predisposition of blacks presenting with a more advanced disease stage as demonstrated in 
this study population.
4.5 Evaluation of race and treatment outcomes
Crude analysis using non-parametric Kruskal-Wallis tests to analyse treatment outcomes for 
blacks using the endpoint of PFS demonstrated that blacks with metastatic disease had a 
significantly shorter PFS (p = 0.003) than whites with equivalent disease stage. 
Cox regression analysis to assess the impact of race on PFS in the different stages of disease 
did not demonstrate any significant predictive value of race on PFS. This was confounded by 
only 55.2% of patients with metastatic disease and 66.4% of patients with all stages of 
disease (metastatic and non-metastatic) being evaluated due to missing values and censored 
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cases. Greater diligence in record-keeping to allow for a more comprehensive analysis of data 
is necessary to address the predictive value of race on treatment outcome in sub-Saharan 
Africa. 
Nonetheless, these findings are consistent with the predominance of clinical evidence which 
suggests that equal treatment yields equal outcome and race need not have an impact on 
patient survival. Most clinical studies conclude that race is not an independent predictor of 
treatment failure. Specifically after evaluating other prognostic factors such as stage, grade, 
and co-morbid disease, race is not predictive of poor outcomes after treatment with radiation,
radical prostatectomy, hormone therapy, or chemotherapy [13-14]. 
Higher PCa mortality rates in black compared to white patients may be explained by their 
presentation at later stages with higher grade tumours and due to differences in their age and 
treatment. More advanced disease stage at diagnosis had the largest impact on explaining the 
greater likelihood for black patients to die of their disease [14]. 
Population-based patterns of care studies demonstrate racial differences in the treatment and 
care administered. The proportion of black men obtaining optimal high-quality care is lower 
than the proportion of whites getting optimal high-quality care. Blacks are less likely to 
benefit from aggressive therapy for localised disease and they are less likely to receive
intense observation while on “watch and wait” therapy [13].
Chapter 4: Discussion
43
4.6 Compliance to treatment and follow-up
It was hypothesised that economically disadvantaged race groups would display poorer levels 
of compliance to treatment and follow-up. While the Indian population group demonstrated a 
tendency towards better compliance, the numbers in this race group were insufficient. There 
was no evidence of disparity in compliance between whites and blacks. 
4.7 Study limitations
The following limitations were noted in the study:
1. Missing values due to inadequate record keeping.
2. No routine record of presence or absence of perineural invasion on histology.
3. Sample population drawn exclusively from the state sector not reflecting the 
demographic findings of patients in the private sector, where it must be presumed that 
there is a higher incidence of patients presenting with organ-confined disease due to 
benefits of screening. 
4. Short follow-up period may have confounded interpretation of treatment outcomes,
especially in patients with biochemical failure and hormone refractory disease. 
5. Data on clinical presentation (symptoms, signs and complications) and treatment 




There appears to be a disproportionately higher incidence of PCa in the white population but 
the evidence is presumptive rather than conclusive. Socio-economic differences across racial 
lines certainly deserve greater mention when analysing data in a uniquely South African 
context. This may mask the higher incidence of PCa one would expect in blacks when 
compared to whites extrapolating from the disparities noted in AAM and EAM. 
This study noted interesting correlates between the sub-Saharan black population and that of 
AAM. This is reflected in the higher median PSA levels on disease presentation and more 
advanced disease presentation when compared to white population groups. The impact of 
race on treatment outcomes revealed contradictory results between the crude analysis and 
Cox regression analysis and further research is warranted to explore this aspect in greater 
detail. 
The results of this study necessitate the implementation of targeted study initiatives with end 
points designed to detect the disease early in the black population and begin appropriate 
management. A commitment to address gross disparities in socio-economic status between 
the race groups is paramount to eradicate the racial bias that exists in terms of accessibility 
and affordability to healthcare and PCa screening programs.
In addition, there must be more education about PCa and its consequences in the black 
population group along with improved support initiatives for patients and their families. 
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The WHO estimates that up to 80% of the population in Africa makes use of traditional 
medicine. In Sub-Saharan Africa, the ratio of traditional healers to the population is 
approximately 1:500, while medical doctors have a 1:40 000 ratio to the rest of the 
population. It is apparent that traditional healers play a significant role in the lives of African 
people and have the potential to serve as crucial components of a comprehensive health care 
strategy [15]. This highlights the need for cultural sensitivity and also dictates collaboration 
with traditional healers in our context to raise awareness about PCa and the available 
treatment options.
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Family history of prostate cancer
Date of first consultation
Tumour Risk Profile
Stage( TNM)
a. Clinical stage: 
b. Pathological stage: ____________
Gleason Score
Perineural Invasion






Localised Disease ( T1/T2 ) Yes / No
Treatment modality
1. Neoadjuvant Hormonal 
Treatment
2. External Beam Radiotherapy
with Concurrent Hormonal 
Treatment
3. Adjuvant Hormonal Treatment
i. Drug/s: _________________
ii.    Duration:_______________
4. Radical Prostatectomy









Locally Advanced Disease ( T3/T4 ) Yes / No
Treatment modality
1. Neoadjuvant Hormonal Treatment
2. External Beam Radiotherapy with 
Concurrent Hormonal Treatment















PSA reading post curative treatment 
modality
Date:                         PSA:
3 consecutive PSA rises Date:                          PSA:
Date:                          PSA:
Date:                          PSA:
Treatment modality on diagnosis of 





4. Surgical Castration (BSO)
5. Other( specify) 
Progression free survival (PFS)










2. Surgical Castration (BSO)













Hormone Refractory Disease Yes / No
Number of hormonal manipulations
(including BSO) prior to diagnosis of 
hormone refractory disease
Time to hormone refractory disease






3. Chemotherapy and Hormonal 
Therapy
i. Drug/s________________
4. Best supportive care
5. Other (specify)
Time to biochemical response on 
chemotherapy (TTBR)
Progression Free Survival (PFS)







History of missed appointments /1
Documented non-compliance on 
treatment
/1
Compliance Score /2
